Posted in | News | Nanomedicine | Nanotoxicology

Research Groups Develop New Tools to Control Cells

BioInterfaces represents an ambitious new "Key Technologies" research programme supported by the Helmholtz Association, the largest German scientific funding organization. The programme brings together a team of biologists, chemists, physicists, materials scientists and informaticians. With an annual budget of approximately 20 Million Euro, the 67 research teams will work closely together to develop innovative tools and technologies for precisely controlling the behaviour of cells.

These are fibroblasts labeled for actin (green) growing in a fibronectin-coated (red), three-dimensional glass scaffold (blue) created by Direct-Laser-Writing. Credit: (Image by Franziska Klein and Martin Bastmeyer)

This will lead, for example, to new ways of growing stem cells, or manipulating cells in the organism and in bioreactor systems. These key technologies will ultimately contribute to the development of new therapies for many degenerative diseases that affect muscle, the retina or the central nervous system. In addition, BioInterfaces aims to control or inhibit bacterial cells that form biofilms on man-made surfaces, another area of immense technical relevance.

"The basic philosophy of the BioInterfaces programme is to learn from nature and then copy it. So, the first stage of our strategy involves a focused, innovative, large-scale analysis to learn more about the natural control mechanisms of cells and how optimally to manipulate them", says Professor Uwe Str?hle, speaker of the program and head of the Institute of Toxicology and Genetics. "This will be achieved by a close partnership between biologists and technology developers. In the subsequent stages, multifunctional molecular devices or advanced surface modifications will be designed and built in order to target and interact with the key molecular control points and thereby to control cell behaviour."

The interdisciplinary nature of the BioInterfaces programme demands a new generation of scientists. The programme has therefore just launched the BioInterfaces Postgraduate School that will provide interdisciplinary training for approximately 90 PhD students. Students will be offered introductory courses covering all the participating disciplines. This school will foster cross-talk between the BioInterfaces research fields through the funding of interdisciplinary and "twinning" student projects.

Reflecting the Helmholtz research philosophy, the BioInterfaces researchers have access to or operate large scale infrastructures such as the largest fish facility in Europe, the ANKA synchrotron radiation source, a large computing and data storage facility, microand nano-fabrication facilities, and advanced surface analysis technology. The programme is based at the campus north of KIT, the Forschungszentrum Karlsruhe. This large Helmholtz research center encompasses a research expertise in micro- and nanotechnology but is also the home for basic biology research. Importantly, BioInterfaces establishes a regional focus since it involves a strong partnership with the University of Heidelberg, recently promoted to the "elite class" of German universities. Strategically, BioInterfaces represents a key programme that demonstrates the great potential offered by KIT.

The Karlsruhe Institute of Technology (KIT) is the merger of the Forschungszentrum Karlsruhe, member of the Helmholtz Association, and the Universit?t Karlsruhe. This merger will give rise to an institution of nternationally excellent research and teaching in natural and engineering sciences. In total, the KIT has 8000 employees and an annual budget of 700 million Euros. The KIT focuses on the knowledge triangle of research ¨C teaching ¨C innovation.

The Karlsruhe institution is a leading European energy research center and plays a visible role in nanosciences worldwide. KIT sets new standards in teaching and promotion of young scientists and attracts top scientists from all over the world. Moreover, KIT is a leading innovation partner of industry.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.